There are currently no pharmacological treatments available that completely halt or reverse
the progression of Parkinson's Disease (PD). Hence, there is an unmet need for …

Abstract Poly (ADP-ribose) polymerase-1 (PARP-1) is the most extensively studied member
of the PARP superfamily, with its primary function being the facilitation of DNA damage …

Intrinsically disordered proteins (IDPs) are proteins that perform important biological
functions without well‐defined structures under physiological conditions. IDPs can form …

Parkinson's disease (PD) is a common, chronic, and progressive degenerative disease of
the central nervous system for which there is no effective treatment. Gastrodia elata is a well …

The misfolding and aggregation of the presynaptic protein α-synuclein (α-syn) is a
pathological hallmark of Parkinson's disease (PD). Targeting α-syn has emerged as a …

Targeted protein degradation (TPD) is a rapidly expanding field, with various PROTACs
(proteolysis-targeting chimeras) in clinical trials and molecular glues such as …

A proteostasis network represents a sophisticated cellular system that controls the whole
process which leads to properly folded functional proteins. The imbalance of proteostasis …

Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder, yet
effective treatments able to stop or delay disease progression remain elusive. The …

Abstract Alpha-synuclein (α-syn) is a presynaptic and nuclear protein that has been
inextricably linked to Parkinson's disease (PD). It regulates the presynaptic activities of …

Interfering with the aggregation of the protein alpha-synuclein (aSyn) has been a topic of
research for> 25 years, as this protein is found in pathognomonic protein aggregates in the …